Fig. 3: Magnitude of anti-SARS-CoV-2 T cell and IgG responses measured in capillary blood samples.

a SARS-CoV-2-specific IFN-γ⁺ T cell responses were measured using the capillary whole blood assay and sub-divided based on participant vaccination and prior SARS-CoV-2 (PCR and/or lateral flow test confirmed) infection status. ‘Vac + /Inf + ’ n = 42 (green), ‘Vac + /Inf-’ n = 158 (blue), ‘Vac-/Inf + ’ n = 33 (yellow), ‘Vac-/Inf-’ n = 37 (grey). ****P < 0.0001, ***P = 0.0001, *(Vac + /Inf- vs. Vac-/Inf-) P = 0.045, *(Vac-/Inf+ vs. Vac-/Inf-) P = 0.014. SARS-CoV-2-specific IgG-binding responses targeting spike receptor binding domain (‘RBD’) (b; ****P < 0.0001, ns: not significant), spike subunit 1 (‘S1’) (c; ****P < 0.0001, ns: not significant), spike subunit 2 (‘S2’) (d; ****P < 0.0001, ***P = 0.0005, *P = 0.016) and nucleocapsid (‘N’) (e; ****P < 0.0001, ns not significant) were measured using the venous whole blood assay and sub-divided based on participant vaccination and prior SARS-CoV-2 (PCR and/or lateral flow test confirmed) infection status. ‘Vac + /Inf + ’ n = 46 (green), ‘Vac + /Inf-’ n = 182 (blue), ‘Vac-/Inf + ’ n = 34 (yellow), ‘Vac-/Inf-’ n = 37 (grey). Comparisons used Kruskal-Wallis tests with correction for multiple comparisons using Dunn’s tests. Data are presented as box plots (centre line at the median, upper bound at 75th percentile, lower bound at 25th percentile) with whiskers at minimum and maximum values. Each dot represents one donor. Source data are provided as a Source Data file.